OSA Stock Price, ProSomnus, Inc. Quote, Chart

Market Summary

USD0.03-0.02

Market Closed

-40.00%

OSA Stock Price

View Fullscreen

OSA RSI Chart

OSA Valuation

Market Cap

521.8K

Price/Earnings (Trailing)

-0.04

Price/Sales (Trailing)

0.02

EV/EBITDA

-1.03

Price/Free Cashflow

-0.03

OSA Price/Sales (Trailing)

OSA Profitability

Operating Margin

49.77%

EBT Margin

-51.25%

Return on Equity

-5.5K%

Return on Assets

-57.63%

Free Cashflow Yield

-3.1K%

OSA Fundamentals

OSA Revenue

Revenue (TTM)

29.3M

Rev. Growth (Yr)

28.4%

Rev. Growth (Qtr)

-4.85%

OSA Earnings

Earnings (TTM)

-13.8M

Earnings Growth (Yr)

149.93%

Earnings Growth (Qtr)

150.09%

Breaking Down OSA Revenue

Last 7 days

66.7%

Last 30 days

-89.4%

Last 90 days

-93.0%

Trailing 12 Months

-99%

How does OSA drawdown profile look like?

OSA Financial Health

Current Ratio

0.3

Debt/Equity

48.92

Debt/Cashflow

-1.28

OSA Investor Care

Shares Dilution (1Y)

6.21%

Diluted EPS (TTM)

-1.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	29.3M	0	0	0
2023	21.5M	23.5M	25.6M	27.7M
2022	15.4M	16.7M	18.1M	19.4M
2021	0	0	0	14.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ProSomnus, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 15, 2024	dow brian b	acquired	-	-	315,742	chief financial officer
Feb 15, 2024	liptak len	acquired	-	-	1,322,760	chief executive officer
Feb 15, 2024	kim sung	acquired	-	-	315,742	chief technical officer
Oct 16, 2023	dow brian b	acquired	-	-	93,750	chief financial officer
Oct 16, 2023	rikkers laing	acquired	-	-	192,500	-
Oct 16, 2023	rikkers laing	sold (taxes)	-70,131	0.855	-82,025	-
Oct 16, 2023	liptak len	acquired	-	-	168,750	chief executive officer
Oct 16, 2023	kim sung	acquired	-	-	93,750	chief technical officer

Which funds bought or sold OSA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Shaolin Capital Management LLC	reduced	-0.39	-954	2,242	-%
May 15, 2024	CITADEL ADVISORS LLC	added	0.47	-155	348	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	7.37	-2,463	4,076	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	unchanged	-	-10,726	14,843	-%
May 15, 2024	Aristides Capital LLC	unchanged	-	-851	2,025	-%
May 15, 2024	Manatuck Hill Partners, LLC	unchanged	-	-316	749	-%
May 15, 2024	RIVERNORTH CAPITAL MANAGEMENT, LLC	unchanged	-	-600	1,200	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-74.00	104	-%
May 15, 2024	Altium Capital Management LP	unchanged	-	-1,260	3,000	-%
May 15, 2024	Walleye Trading LLC	sold off	-100	-11,284	-	-%

Are Funds Buying or Selling OSA?

Are funds buying OSA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OSA

No. of Funds

Unveiling ProSomnus, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	walleye capital llc	6.31%	1,103,690	SC 13G
Feb 12, 2024	polar asset management partners inc.	3.8%	638,596	SC 13G/A
Dec 08, 2023	smc holdings ii, lp	36.6%	9,327,557	SC 13D/A
Oct 23, 2023	smc holdings ii, lp	11.7%	2,130,630	SC 13D

Recent SEC filings of ProSomnus, Inc.

View All Filings

Date Filed	Form Type	Document
May 20, 2024	10-Q	Quarterly Report
May 16, 2024	8-K	Current Report
May 15, 2024	NT 10-Q	NT 10-Q
May 08, 2024	8-K	Current Report
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 25, 2024	25-NSE	25-NSE
Apr 19, 2024	8-K	Current Report
Apr 18, 2024	8-K	Current Report
Mar 27, 2024	10-K	Annual Report

Peers (Alternatives to ProSomnus, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	179.1B	40.3B	-4.03%	-4.89%	31.84	4.44	-2.84%	-3.08%
BDX	67.9B	19.7B	0.29%	-6.47%	50.91	3.44	4.82%	-17.56%
ALGN	19.9B	3.9B	-11.75%	-12.29%	42.97	5.07	5.72%	46.72%
BAX	17.5B	14.9B	-12.77%	-19.14%	6.62	1.18	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	6.68%	25.84%	31.49	2.78	6.16%	35.06%
HSIC	9.4B	12.5B	3.39%	-5.42%	24.18	0.75	-0.61%	-18.83%
BIO	8.3B	2.6B	3.50%	-25.22%	-25.61	3.17	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.51%	-28.42%	-62.64	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.96%	30.96%	-216.43	8.91	30.82%	65.57%
PDCO	2.2B	6.6B	-4.69%	-8.59%	11.48	0.34	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	4.60%	-14.00%	-1.87	0.4	7.94%	-1661.78%
ANIK	381.8M	169.3M	-0.35%	-4.56%	-4.97	2.26	7.49%	-244.90%
ANGO	234.3M	324.0M	-6.55%	-39.32%	-1.22	0.72	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.09%	-2.46	1.11	14.25%	-10.06%
AEMD	1.1M	3.7M	-70.55%	34.38%	-0.09	0.3	5.77%	8.23%

ProSomnus, Inc. News

Latest updates

ProSomnus, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-4.9%	7,458,000	7,838,265	7,071,445	6,933,910	5,808,380	5,791,969	4,997,979	4,859,909	3,743,143	-
Cost Of Revenue	-7.3%	3,833,000	4,133,502	3,580,073	3,170,794	2,756,631	2,686,525	2,540,288	2,321,692	1,578,496	-
Gross Profit	-	-	-	3,491,372	3,763,116	3,051,749	3,105,450	2,457,691	2,538,217	2,164,647	-
Costs and Expenses	-55.9%	9,249,000	20,977,662	7,707,448	9,498,878	9,952,000	-	4,584,951	3,971,894	-	-
Operating Expenses	-	-	-	-	-	7,196,024	-	-	-	4,028,787	-
S&GA Expenses	-41.5%	1,976,000	3,377,723	3,240,511	3,642,718	2,824,048	2,414,827	2,319,362	2,013,392	2,117,419	-
R&D Expenses	-30.1%	955,000	1,366,930	1,040,065	1,376,036	1,018,969	1,065,479	688,540	669,348	557,633	-
EBITDA Margin	5.3%	-0.29	-0.31	-0.31	-0.02	-0.20	-0.03	-0.11	-0.11	-0.12	-0.14
Interest Expenses	-22.6%	1,146,000	1,480,745	1,489,286	1,240,159	1,171,810	2,405,224	1,421,702	1,197,237	1,095,837	-
Income Taxes	-	-	-	-	-	-	-	-1,172	3,567	4,085	-
Earnings Before Taxes	-	-	-	-11,238,803	904,930	-6,892,171	2,208,020	-3,548,962	-2,823,645	-2,980,733	-
EBT Margin	5.6%	-0.51	-0.54	-0.59	-0.31	-0.52	-0.37	-0.33	-0.36	-0.39	-0.42
Net Income	150.1%	3,441,000	-6,868,956	-11,238,803	904,930	-6,892,171	2,208,340	-3,548,962	-2,823,645	-2,980,733	-5,820,255
Net Income Margin	46.1%	-0.47	-0.87	-0.59	-0.31	-0.52	-0.37	-0.84	-0.70	-0.58	-0.42
Free Cashflow	52.4%	-2,556,000	-5,375,195	-3,218,027	-4,933,844	-4,066,934	-6,499,233	-1,574,229	-1,927,294	-1,592,244	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet								(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4
Assets	-9.2%	24.00	26.00	30.00	25.00	29.00	33.00	29.00	8.00
Current Assets	-18.6%	12.00	14.00	18.00	12.00	17.00	21.00	29.00	4.00
Cash Equivalents	-34.7%	4.00	6.00	12.00	6.00	12.00	16.00	2.00	2.00
Inventory	-0.8%	2.00	2.00	2.00	1.00	1.00	1.00	-	0.00
Net PPE	-5.7%	3.00	3.00	4.00	3.00	3.00	2.00	-	3.00
Liabilities	-11.8%	47.00	53.00	52.00	51.00	56.00	54.00	38.00	22.00
Current Liabilities	171.6%	39.00	14.00	12.00	9.00	8.00	7.00	1.00	7.00
Long Term Debt	-100.0%	-	12.00	13.00	13.00	14.00	14.00	-	-
LT Debt, Current	499.2%	13.00	2.00	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	12.00	13.00	13.00	14.00	14.00	-	-
Retained Earnings	1.5%	-231	-234	-228	-216	-217	-210	-0.39	-203
Additional Paid-In Capital	0.2%	197	197	195	191	191	190	0.00	150
Shares Outstanding	0.0%	17.00	17.00	16.00	16.00	16.00	16.00	25.00	25.00
Float	-	-	-	-	26.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	56.6%	-2,522	-5,811	-2,526	-4,696	-3,092	-5,476	-1,475	-1,824	-1,462	-	-
Share Based Compensation	-10.2%	414	461	147	343	226	2,152	1.00	-	-	-	-
Cashflow From Investing	-107.8%	-34.00	436	-691	-237	-974	-1,022	-99.04	-102	-129	-	-
Cashflow From Financing	-179.2%	-330	416	9,064	-450	-288	20,255	2,568	1,428	1,758	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OSA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 7,458	$ 5,808
Operating expenses:
Cost of revenue	3,833	2,756
Sales and marketing	1,976	2,824
General and administrative	2,485	3,353
Research and development	955	1,019
Total operating expenses	9,249	9,952
Net loss from operations	(1,791)	(4,144)
Other income (expense)
Interest expense, net	(1,146)	(1,172)
Change in fair value of earnout liability	490	1,500
Change in fair value of debt	5,885	(1,827)
Change in fair value of warrant liability	58	(843)
Other expense, net	(55)	(406)
Total other income (expense), net	5,232	(2,748)
Net income (loss)	$ 3,441	$ (6,892)
Net income (loss) per share attributable to common stockholders, basic	$ 0.20	$ (0.43)
Net income (loss) per share attributable to common stockholders, diluted	$ (0.02)	$ (0.43)
Weighted average shares of Common Stock, basic	17,392,983	16,041,464
Weighted-average common shares outstanding - Diluted	64,618,931	16,041,464

OSA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 3,477	$ 6,363
Restricted cash	700	700
Accounts receivable, net	4,339	3,839
Inventory	2,023	2,039
Prepaid expenses and other current assets	1,111	1,369
Total current assets	11,650	14,310
Property and equipment, net	3,166	3,358
Finance lease right-of-use assets	3,603	3,265
Operating lease right-of-use assets	4,981	5,069
Other assets	479	285
Total assets	23,879	26,287
Current liabilities:
Accounts payable	4,532	4,047
Accrued expenses and other current liabilities	5,646	6,756
Equipment financing obligation	59	57
Finance lease liabilities	1,117	1,052
Operating lease liabilities	318	304
Senior Convertible Notes at fair value, current portion	12,734	2,125
Subordinated Convertible Notes at fair value	14,551
Total current liabilities	38,957	14,341
Equipment financing obligation, net of current portion	113	129
Finance lease liabilities, net of current portion	2,256	2,009
Operating lease liabilities, net of current portion	5,134	5,221
Senior Convertible Notes at fair value, net of current portion		12,152
Subordinated Convertible Notes at fair value		18,320
Earnout and warrant liability	168	716
Total liabilities	46,628	52,888
Commitments and contingencies
Redeemable Convertible Series A Preferred Stock, $0.0001 par value, stated value $1,000; 25,000 shares designated at March 31, 2024 and December 31, 2023; 9,436 shares issued and outstanding at March 31, 2024 and December 31, 2023; liquidation preference of $14,154 at March 31, 2024 and December 31, 2023	11,555	11,555
Stockholders' deficit:
Preferred stock, $0.0001 par value, 1,500,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding
Common Stock, $0.0001 par value, 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 17,394,064 and 17,388,599 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	2	2
Additional paid-in capital	197,142	196,731
Accumulated deficit	(231,448)	(234,889)
Total stockholders' deficit	(34,304)	(38,156)
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	23,879	26,287
Series A Redeemable Convertible Preferred Stock
Current liabilities:
Redeemable Convertible Series A Preferred Stock, $0.0001 par value, stated value $1,000; 25,000 shares designated at March 31, 2024 and December 31, 2023; 9,436 shares issued and outstanding at March 31, 2024 and December 31, 2023; liquidation preference of $14,154 at March 31, 2024 and December 31, 2023	$ 11,555	$ 11,555

About ProSomnus, Inc.

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolarygologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.

CEO	Mr. Leonard Liptak
WEBSITE	prosomnus.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	129

ProSomnus, Inc. Frequently Asked Questions

What is the ticker symbol for ProSomnus, Inc.? What does OSA stand for in stocks?

OSA is the stock ticker symbol of ProSomnus, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ProSomnus, Inc. (OSA)?

As of Mon May 20 2024, market cap of ProSomnus, Inc. is 521.82 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OSA stock?

You can check OSA's fair value in chart for subscribers.

What is the fair value of OSA stock?

You can check OSA's fair value in chart for subscribers. The fair value of ProSomnus, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ProSomnus, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OSA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ProSomnus, Inc. a good stock to buy?

The fair value guage provides a quick view whether OSA is over valued or under valued. Whether ProSomnus, Inc. is cheap or expensive depends on the assumptions which impact ProSomnus, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OSA.

What is ProSomnus, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 20 2024, OSA's PE ratio (Price to Earnings) is -0.04 and Price to Sales (PS) ratio is 0.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OSA PE ratio will change depending on the future growth rate expectations of investors.